PMID- 31314750
OWN - NLM
STAT- MEDLINE
DCOM- 20200213
LR  - 20200225
IS  - 1643-3750 (Electronic)
IS  - 1234-1010 (Print)
IS  - 1234-1010 (Linking)
VI  - 25
DP  - 2019 Jul 17
TI  - Sesamin Promotes Osteoblastic Differentiation and Protects Rats from 
      Osteoporosis.
PG  - 5312-5320
LID - 10.12659/MSM.915529 [doi]
AB  - BACKGROUND Osteoporosis is a common osteopathy, resulting in fractures, 
      especially in elder people. Sesamin has many pharmacological effects, including 
      supplying calcium. However, how sesamin might prevent osteoporosis is still under 
      study. MATERIAL AND METHODS Bone marrow stromal cells (BMSCs) extracted from rat 
      femur were induced for osteoblastic differentiation. Cell proliferation, alkaline 
      phosphatase (ALP), osterix (OSX), SRY-box 9 (SOX9), runt-related transcription 
      factor 2 (RUNX2), osteocalcin (OCN), ss-catenin, low density lipoprotein 
      receptor-related protein 5 (LRP5), and glycogen synthase kinase-3ss (GSK-3ss) 
      levels in BMSCs were detected in the presence or absence of sesamin (1 muM or 10 
      microM). In addition, FH535 (1 muM) was used to silence Wnt/ss-catenin in vitro. 
      Ovariectomized (OVX) rats were established and intragastrically administrated 
      sesamin (80 mg/kg), and then the rat bones were analyzed by micro-computed 
      tomography. Osteocalcin and collagen type I were measured in the rat femurs. 
      RESULTS Sesamin had no influence on BMSC proliferation. Higher sesamin 
      concentration promoted Wnt/ss-catenin activity and enhanced more expressions of 
      ALP, OSX, SOX9, RUNX2, and OCN, gradually and significantly (P<0.05). Silencing 
      Wnt/ss-catenin weakened the enhancement on RUNX2 and OCN expression. Sesamin (80 
      mg/kg) promoted bone structure in ovariectomized rats, and significantly enhanced 
      osteocalcin and collage type I expression (P<0.05). CONCLUSIONS Sesamin promoted 
      osteoblastic differentiation of rat BMSCs by regulating the Wnt/ss-catenin 
      pathway, and improved rat bone structure. Sesamin could have therapeutic and 
      preventive effects on osteoporosis.
FAU - Ma, Zhong-Ping
AU  - Ma ZP
AD  - Department of Orthopedics, The Second Affiliated Hospital of Inner Mongolia 
      Medical University, Hohhot, Inner Mongolia, China (mainland).
FAU - Zhang, Zhi-Feng
AU  - Zhang ZF
AD  - Department of Orthopedics, The Second Affiliated Hospital of Inner Mongolia 
      Medical University, Hohhot, Inner Mongolia, China (mainland).
FAU - Yang, Yi-Feng
AU  - Yang YF
AD  - Department of Orthopedics, The Second Affiliated Hospital of Inner Mongolia 
      Medical University, Hohhot, Inner Mongolia, China (mainland).
FAU - Yang, Yun
AU  - Yang Y
AD  - Department of Orthopedics, The Second Affiliated Hospital of Inner Mongolia 
      Medical University, Hohhot, Inner Mongolia, China (mainland).
LA  - eng
PT  - Journal Article
DEP - 20190717
PL  - United States
TA  - Med Sci Monit
JT  - Medical science monitor : international medical journal of experimental and 
      clinical research
JID - 9609063
RN  - 0 (Collagen Type I)
RN  - 0 (Dioxoles)
RN  - 0 (Lignans)
RN  - 0 (beta Catenin)
RN  - 104982-03-8 (Osteocalcin)
RN  - EC 3.1.3.1 (Alkaline Phosphatase)
RN  - S7946O4P76 (sesamin)
SB  - IM
MH  - Alkaline Phosphatase/metabolism
MH  - Animals
MH  - Bone and Bones/metabolism
MH  - Cell Differentiation/drug effects
MH  - Cell Proliferation/drug effects
MH  - China
MH  - Collagen Type I/metabolism
MH  - Dioxoles/metabolism/*pharmacology
MH  - Female
MH  - Lignans/metabolism/*pharmacology
MH  - Mesenchymal Stem Cells
MH  - Osteoblasts/*drug effects/metabolism
MH  - Osteocalcin/metabolism
MH  - Osteogenesis/drug effects
MH  - Osteoporosis/drug therapy/*metabolism/prevention & control
MH  - Ovariectomy
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Wnt Signaling Pathway/drug effects
MH  - beta Catenin/metabolism
PMC - PMC6659468
COIS- Conflict of interests None.
EDAT- 2019/07/18 06:00
MHDA- 2020/02/14 06:00
PMCR- 2019/07/17
CRDT- 2019/07/18 06:00
PHST- 2019/07/18 06:00 [entrez]
PHST- 2019/07/18 06:00 [pubmed]
PHST- 2020/02/14 06:00 [medline]
PHST- 2019/07/17 00:00 [pmc-release]
AID - 915529 [pii]
AID - 10.12659/MSM.915529 [doi]
PST - epublish
SO  - Med Sci Monit. 2019 Jul 17;25:5312-5320. doi: 10.12659/MSM.915529.